MET and small cell lung carcinoma: Here we have not only confirmed these observations but also extended them by providing direct evidence for anti-oncogenic properties of a small molecule inhibitor, PHA-665752, in MET mutant SCLC cell lines, independently of their sensitivity/resistance to chemotherapy.